Clinical Trials Logo

Melatonin clinical trials

View clinical trials related to Melatonin.

Filter by:

NCT ID: NCT04230707 Enrolling by invitation - Anxiety Clinical Trials

Endogenous Melatonin Levels on Anxiety in Living Liver Donors

Start date: October 1, 2019
Phase:
Study type: Observational

Interesting in living liver donor transplantation have greatly increased because of inadequacy of cadaveric organs and the inability to supply the growing need for cadaveric transplantation. Surgical procedures applied to living liver donors do not only physically demand organs, but can also cause psychological burden. It has been reported that melatonin had antioxidant, antinociceptive, hypnotic, anticonvulsant, neuroprotective, anxiolytic, sedative and analgesic properties. It was shown to administration of exogenous melatonin has been increase sedation and decrease anxiety in the preoperative period compared to placebo. The aim of this study; To investigate preoperative and postoperative anxiety levels of CKV and to exam the relationship between anxiety levels and endogenous melatonin levels.

NCT ID: NCT03966950 Recruiting - Clinical trials for Postoperative Complications

Use of Melatonin for Preventing POCD in Transurethral Prostate Resection Under Spinal Anesthesia

Start date: June 26, 2017
Phase: N/A
Study type: Interventional

This study aims to evaluate the possible effect of melatonin on prevention of cognitive dysfunction in the postoperative period of elderly patients undergoing transurethral resection of the prostate (TURP) under spinal anesthesia

NCT ID: NCT03725267 Terminated - Acute Kidney Injury Clinical Trials

Melatonin for Renal Protection in Patients Receiving Polymyxin B

Start date: October 1, 2018
Phase: Phase 2
Study type: Interventional

This study has the objective to evaluate the effect in renal function of 30mg of Melatonin versus placebo in patients ≥18 years old treated with polymyxin B. The development of nephrotoxicity will be evaluated by RIFLE(Risk, Injury, Failure, Loss, End stage renal disease) score and KIM-1 urinary biomarker for the first 14 days of polymyxin B therapy.

NCT ID: NCT03519750 Completed - Pharmacokinetics Clinical Trials

Pharmacokinetics of Intravenous, Rectal, Intravesical, Vaginal, and Transdermal Melatonin in Healthy Female Volunteers

Start date: November 1, 2018
Phase: Phase 1
Study type: Interventional

We will investigate the safety and pharmacokinetics of melatonin, when administered rectally, intravesically, vaginally and transdermally. We will recruit 10 healthy female volunteers. The volunteers will have melatonin administered over 5 days; intravenously, rectally, intravesically, vaginally and transdermally. The participants will be followed for 24-48 hours with blood samples and questions about adverse events. There will be a wash-out between each session of a minimum of 7 days.

NCT ID: NCT03478306 Completed - Clinical trials for Diabetic Retinopathy

Diabetic Retinopathy: Effects of Melatonin Treatment on Visual Functions and Circadian Rhythm

Start date: March 27, 2018
Phase: Phase 3
Study type: Interventional

This study evaluates the effect of melatonin 4 mg on circadian rhythm and visual function of patients with diabetes mellitus. Half of the patients will receive melatonin (arm-1) and the other half will receive placebo (arm-2), both groups in 3 weeks. After a week of washout, the patients will cross over to the other treatment arm.

NCT ID: NCT03464084 Completed - Circadian Rhythm Clinical Trials

Interaction of Melatonin With MTNR1B Genotype on Glucose Control - Study 2

Start date: February 17, 2018
Phase: N/A
Study type: Interventional

This project aims to test the impact of melatonin and MTNR1B variation on regulation glucose regulation in a highly controlled in-laboratory setting and ex vivo in pancreatic islets.

NCT ID: NCT03230630 Completed - Clinical trials for Myocardial Infarction

Plasma Melatonin AND Mortality After Acute Myocardial Infarction

Start date: January 1, 2013
Phase: N/A
Study type: Observational

Pre-clinical and clinical studies have demonstrated that melatonin has cardio-protection effects. Melatonin has anti-inflammatory, antioxidant, antihypertensive, antithrombotic and antilipaemic properties, which plays important roles in a variety of cardiovascular pathophysiologic processes. Nocturnal melatonin levels decreased after AMI, and lower serum melatonin concentrations after AMI are associated with more heart failure and cardiac death and left ventricular remodeling. Moreover in women with increased BMI, lower melatonin secretion is associated with higher risks of MI. Early-morning blood collection is easier in clinical practice. Therefore, the investigators carried out a cohort study to evaluate the prognostic value of plasma soluble melatonin in hospitalized patients with acute myocardial infarction (AMI).

NCT ID: NCT03107702 Enrolling by invitation - POSTOPERATIVE PAIN Clinical Trials

Melatonin Level and Postoperative Analgesia Consumption in Bariatric Surgery Patients.

Start date: March 29, 2017
Phase: N/A
Study type: Observational

Bariatric surgical procedures are associated with low short-term mortality and may be associated with long-term reductions in all-cause, cardiovascular, and cancer-related mortality. This surgeries are major surgeries include risk of mortality still. Melatonin is a hormone secreted from the pineal gland. Melatonin is an antioxidant, antinociceptive, hypnotic, anticonvulsant, neuroprotective, anxiolytic, sedative and analgesic. Melatonin is neurohormone with the profile of a novel hypnotic-anesthetic agent. The purpose of this study is to investigate the preoperative, perioperative and postoperative melatonin levels in bariatric surgery under general anesthesia and to investigate the relationship between melatonin level and analgesia requirement.

NCT ID: NCT03013790 Recruiting - Delirium Clinical Trials

Melatonin Use in the Intensive Care Elderly Population

MICE
Start date: December 2016
Phase: Phase 4
Study type: Interventional

The investigators are studying the use of Melatonin in non-ventilated patients over the age of 65. Primary endpoint will be assesments of delirium, with secondary endpoints to include length of stay, use of anti-psychotic medications, and mortality

NCT ID: NCT02936674 Completed - Melatonin Clinical Trials

Color-dependent Melatonin Suppression

Start date: October 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to examine the effects of complex, broad-band spectra light on the production of melatonin in humans.